The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk A/S NVO reported first-quarter 2025 earnings of 92 cents per American Depositary Receipt (ADR), which matched ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.